Karyopharm Files Chapter 11, Strikes Ayrmid Merger With $55M DIP; Equity Wiped Out
KPTI is trading near its 52-week low of $0.31 (51% below the low).
Summary
Karyopharm filed Chapter 11 and agreed to merge with Ayrmid Ltd. under a prepackaged plan backed by up to $55 million in DIP financing. Common and preferred shareholders are slated to receive nothing — a complete loss.
Key Events · M&A and Partnerships · KPTI
-
Chapter 11 Filed, Ayrmid Merger Agreed
Karyopharm filed voluntary Chapter 11 petitions in the Southern District of Texas to implement a Restructuring Support Agreement providing for a merger with Ayrmid Ltd., parent of Gamida Cell. Ayrmid serves as lead bidder in a court-supervised sale process open to competing bids.
-
Existing Equity Wiped Out
The Prepackaged Plan provides that holders of common stock and Convertible Preferred Stock receive no payment or distribution; the company expects existing equity to have no value and holders to experience a complete loss. Delisting from Nasdaq is expected.
-
$55M DIP Financing Committed
Existing secured lenders committed up to $55 million in debtor-in-possession financing, which together with operating cash is expected to fund the business through the Chapter 11 process, subject to Court approval.
-
Closing Targeted for Q1 2027
The Transaction is expected to close in the first quarter of 2027, subject to conditions in the Chapter 11 plan and Court approval of bidding procedures.
Analysis · KPTI · Life Sciences
Karyopharm has filed for Chapter 11 and agreed to be acquired by Ayrmid Ltd. through a prepackaged plan, with Ayrmid as lead bidder in a court-supervised sale. Existing shareholders get nothing: the plan states holders of common stock and the Convertible Preferred Stock will receive no payment or distribution, and the company expects its equity to have no value and holders to suffer a complete loss. Up to $55 million of new debtor-in-possession financing from existing secured lenders keeps operations running through the sale process, which the company expects to close in the first quarter of 2027. This follows the missed $15.8M debt payment on 2026-09-11 and two short forbearance extensions (2026-10-14 and 2026-10-22) that ran out on November 1 — the forbearance clock expiring is what forced this filing.
At the time of this filing, KPTI was trading at $0.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15M. The 52-week trading range was $0.31 to $10.99. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.